Mink Therapeutics, Inc. · NASDAQ:INKT
Mink Therapeutics — Q2 2026 Earnings Presentation
15 slides from Mink Therapeutics's earnings presentation, Aug 13, 2026
Slide 1: Randomized Phase 2 of agenT-797 as a Pathogen-Agnostic Treatment of Hypoxemic Pneumonia/ARDS
Military Health System Research Symposium – 06 August 2026 Randomized Phase 2 of agenT-797 as a Pathogen-Agnostic Treatment of Hypoxemic Pneumonia/ARDS in Austere and Conflict Environments Terese C. Hammond, MD Program Medical Director, Pulmonary, Critical Care, Neurocritical Care and Sleep Medicine
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Dr. Terese Hammond has served as a Principal Investigator and Clinical Advisor to MiNK Therapeutics. Dr. Hammond is presenting today in her capacity as a practicing clinician and not as a representative of MiNK. The clinical views and interpretations express
Slide 3: Conflict-Driven MDRO Infections Fuel Hypoxemic Pneumonia/ARDS and Demand Pathogen-Agnostic Immune Restoration
Conflict-Driven MDRO Infections Fuel Hypoxemic Pneumonia/ARDS— and Demand Pathogen-Agnostic Immune Restoration Delayed pathogen identification and antibiotic access drive MDRO resistance Multiple MDROs from VAP sputum sample from a war- pressure along evacuation routes and amplify exposure and infec
Slide 4: Restoring Barrier Immunity in MDRO-Complicated Hypoxemic Pneumonia with Off-the-Shelf iNKT Cell Therapy
Restoring Barrier Immunity in MDRO-Complicated Hypoxemic Pneumonia with Off-the-Shelf iNKT Cell Therapy Early Clinical Activity and Phase 2b/3 Expansion Situation. Exposure to MDRO infections exacerbates acute respiratory distress syndrome (ARDS) post-injury/trauma/illness Mission: Restore barrier i
Slide 5: Invariant Natural Killer T (iNKT) Cells: Rapid, Rare, Responsive and Deployable
Invariant Natural Killer T (iNKT) Cells RAPID, RARE, RESPONSIVE and DEPLOYABLE i i Rare. Rapid. Responsive. Deployable. i i
Slide 6: Trial Design Phase 2b/3 Study: agenT-797 in Severe Hypoxemic Pneumonia with ARDS
Trial Design Phase 2b/3 Study: agenT-797 in Severe Hypoxemic Pneumonia with ARDS NCT07615010 Phase: 2b/3 Adaptive (n=80 → n=300) Study Number: C-1300-02 Population: Moderate-to-severe hypoxemic pneumonia Phase 2B Full Analysis by global ARDS definition SOC (Investigator’s SOC choice) Arms: agenT-797
Slide 7: First Treated Patient at First Lviv Territorial Medical Union
First Treated Patient at First Lviv Territorial Medical Union 41 y/o F with poorly controlled diabetes, Antibiotic S. mitis / S. S. A. baumannii P. aeruginosa K. S. mitis Pneumococcal Sepsis, 38.6°C Ampicillin oralis S pneumoniae – – – pneumoniae – I/R Ampicillin/Sulbactam – – R – – – Day 1 Day 21 D
Slide 8: Pt-001 Clinical Activity: Physiologic and Immune Recovery Through Day 28
Pt-001 Clinical Activity: Physiologic and Immune Recovery Through Day 2 1×10⁹ cells + SOC agenT-797 Physiologic and Laboratory Course Through Day 28 Dosed 14 Jul 2026 Gas exchange and organ function Assessment Day 1 Day 7 Day 14 Day 21 Day 28 PaO₂/FiO₂, mmHg 136.5 172.1 244 232.5 399 Respiratory sup
Slide 9: Clinical and BAL Biomarkers Show Coordinated Immune Recovery and Lung Repair Following agenT-797
Clinical and BAL Biomarkers Show Coordinated Immune Recovery and Lung Repair Following agenT-797 Inflammation resolution Immune reconstitution Lung reconstitution Procalcitonin CRP Ferritin Lymphocytes PaO2/FiO2 4 200 4000 1.5 500 400 3 150 3000 1.0 300 x 103 / μl ng / mL mg / L mmHg μg / L 2 100 20
Slide 10: Second Treated Patient at First Lviv Territorial Medical Union
Second Treated Patient at First Lviv Territorial Medical Union 18 y/o M with EtOH associated MVA, Klebsiella pneumoniae Elizabethkingia polytrauma (TBI, chest, long bone), 40.1°C Antibiotic ss. pneumoniae meningoseptica Amikacin R R Day 2 Day 26 Amoxicillin-clavulanic R – acid Gentamicin R – Trimeth
Slide 11: Pt-002 Clinical Activity: Physiologic and Immune Recovery Through Day 28
Pt-002 Clinical Activity: Physiologic and Immune Recovery Through Day 28 Gas exchange and organ function Assessment Day 1 Day 7 Day 14 Day 21 Day 28 PaO₂/FiO₂ 172 171.6 169.2 359.5 350 Respiratory support Invasive MV Invasive MV Invasive MV Invasive MV Room air SOFA-2 score 4 2 3 1 0 Inflammatory ma
Slide 12: Clinical Biomarkers Show Coordinated Immune Recovery Following agenT-797
Clinical Biomarkers Show Coordinated Immune Recovery Following agenT-797 Inflammation resolution Immune reconstitution Lung reconstitution Procalcitonin CRP Ferritin Lymphocytes PaO2/FiO2 1.0 300 1500 2.5 400 0.8 2.0 300 200 1000 0.6 1.5 x 103 / μl ng / mL mg / L mmHg μg / L 200 0.4 1.0 100 500 100
Slide 13: Early Phase 2b Data Show Clinical Recovery with Concordant Immune and Lung Repair Signals
Early Phase 2b Data Show Clinical Recover with Concordant Immune and Lung Repair Signals • 100% 28-day survival in the first evaluable patients, despite severe hypoxemia and polymicrobial/MDRO pneumonia • P/F ratios improved (136 to 388 mmHg and 172 to 467 mmHg), with resolution of ARDS by day 28 in
Slide 14: Acknowledgments
Acknowledgments MiNK Therapeutics First Lviv Territorial Medical Union, St. Panteleimon's Hospital, Lviv, Ukraine Jennifer S. Buell, PhD Maryana Svirchuk Marco A. Purbhoo, PhD Khrystyna Orlynska, MD Thiago Favano, PharmD Demian Kalysh, MD Lilian Guardian, RN, MBA All clinical staff at First Lviv Ter
Slide 15: Allogeneic iNKT Cells for Hypoxemic Pneumonia in a Conflict Zone
Allogeneic iNKT Cells for Hypoxemic Pneumonia in a Conflict Zone Phase 1/2 clinical trial – agenT-797 in ARDS Contact: terese.hammond@kaweahhealth.org